Literature DB >> 318227

Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins.

J J Schrogie1, J D Rogers, K C Yeh, R O Davies, G I Holmes, H Skeggs, C M Martin.   

Abstract

Features of the distribution, metabolism, elimination, and pharmacokinetics of the cephalosporins and cefoxitin must be considered when concentrations of these drugs in biological fluids are interpreted. The extensive (approximately 86%) binding of cefazolin to plasma protein may account for the smaller volume of distribution and slower rate of renal clearance than are observed for cefoxitin, which is less extensively (73%) bound to protein. Results of microbiological assays of drug in urine may be influenced by the extent of metabolism of the drugs, which is 33% for cephalothin but less than 2% for cefoxitin. Elimination of cephalosporins and cefoxitin occurs by both glomerular filtration and tubular secretion and can be inhibited by the concurrent administration of probenecid. The pharmacokinetics of cefoxitin may be described by a linear, two-compartment, open model that has been used to predict levels of drug achieved in serum and urine after various dose regimens, including administration by intravenous bolus or infusion. The bioavailability of intramuscularly administered cefoxitin is equivalent to that of intravenously administered cefoxitin and is 90% complete within 3-4 hr after the dose is given.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 318227     DOI: 10.1093/clinids/1.1.90

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  14 in total

1.  Preclinical Pharmacokinetic and Pharmacodynamic Data To Support Cefoxitin Nebulization for the Treatment of Mycobacterium abscessus.

Authors:  Shachi Mehta; Vincent Aranzana-Climent; Blandine Rammaert; Nicolas Grégoire; Sandrine Marchand; William Couet; Julien M Buyck
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

2.  Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery.

Authors:  Arantxazu Isla; Iñaki F Trocóniz; Ignacio López de Tejada; Silvia Vázquez; Andrés Canut; Jesús Muriel López; María Ángeles Solinís; Alicia Rodríguez Gascón
Journal:  Eur J Clin Pharmacol       Date:  2012-01-15       Impact factor: 2.953

3.  Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

Authors:  K S Israel; H R Black; G L Brier; J D Wolny; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

4.  Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers.

Authors:  S Srinivasan; K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

5.  Pharmacology of ceftizoxime compared with that of cefamandole.

Authors:  H C Neu; S Srinivasan
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

6.  Chemoprophylaxis with cefoxitin and cephalothin in orthopedic surgery: a comparison.

Authors:  M B Rosenfeld; J Campos; K R Ratzan; I Uredo
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

Review 7.  Beta-lactams in sexually transmitted diseases: rationale for selection and dosing regimens.

Authors:  D Kunimoto; R Brunham; A Ronald
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

8.  Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.

Authors:  P H Vlasses; A M Holbrook; J J Schrogie; J D Rogers; R K Ferguson; W B Abrams
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

9.  Concentrations of cefoxitin in gallbladder bile of cholecystectomy patients.

Authors:  J F Hansbrough; J E Clark
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

10.  Relevance of serum protein binding of cefoxitin and cefazolin to their activities against Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; J C van den Berg; T B Vree; A M Baars; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.